

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

1 **Comparative Effect of Metformin versus Sulfonylureas with Dementia and Parkinson's**  
2 **Disease Risk in US patients over 50 with Type 2 Diabetes Mellitus**

3 Danielle Newby <sup>a,b\*</sup>, Andrew B Linden <sup>c</sup>, Marco Fernandes <sup>a</sup>, Yasmina Molero <sup>d,e</sup>, Laura  
4 Winchester <sup>a</sup>, William Sproviero <sup>a</sup>, Upamanyu Ghose <sup>a</sup>, Qingqin S Li <sup>f</sup>, Lenore J Launer <sup>g</sup>,  
5 Cornelia van Duijn <sup>c,h</sup> & Alejo J Nevado-Holgado <sup>a</sup>

6 <sup>a</sup> University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK

7 <sup>b</sup> Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and  
8 Musculoskeletal Sciences, University of Oxford, Oxford, UK

9 <sup>c</sup> Nuffield Department of Population Health, University of Oxford, Big Data Institute, Li Ka Shing  
10 Centre for Health Information and Discovery, Oxford, UK

11 <sup>d</sup> Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institute, Stockholm, Sweden

12 <sup>e</sup> Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

13 <sup>f</sup> Janssen Research & Development, LLC, Titusville, NJ 08560, USA

14 <sup>g</sup> National Institute of Aging, Boston, USA

15 <sup>h</sup> Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands

16

17 **Corresponding author:** Dr Danielle Newby [danielle.newby@ndorms.ox.ac.uk](mailto:danielle.newby@ndorms.ox.ac.uk)

18 **Current address:** Centre for Statistics in Medicine, Nuffield Department of Orthopaedics,  
19 Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK Tel.: +44 (0)  
20 1865 227 374

21 **Word count:** 3930 (excluding title page, abstract, references, figures, and tables)

22 **Keywords:** diabetes, metformin, dementia, Parkinson's disease, drug repurposing

23 **Abbreviations:** AD: Alzheimer's disease, PD: Parkinson's disease, VD: vascular dementia,  
24 MCI: mild cognitive impairment, CKD: Chronic Kidney Disease, eGFR: estimated glomerular  
25 filtration rate, HbA1c: hemoglobin A1c, NSAIDs: Non-steroidal anti-inflammatory drugs,  
26 COPD: Chronic obstructive pulmonary disease

27 **Short title:** Metformin versus sulfonylureas on Dementia and Parkinson's risk

28

29

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

30 **ABSTRACT**

31 **Introduction:** Type 2 diabetes is a risk factor for dementia and Parkinson's disease (PD).  
32 Drug treatments for diabetes, such as metformin, could be used as novel treatments for  
33 these neurological conditions. Using electronic health records from the USA (OPTUM®  
34 EHR) we aimed to assess the association of metformin with all cause dementia, dementia  
35 subtypes and PD compared to sulfonylureas.

36 **Research Design and Methods:** A new user comparator study design was conducted in  
37 patients  $\geq 50$  years old with diabetes who were new users of metformin or sulfonylureas  
38 between 2006-2018. Primary outcomes were all cause dementia and PD. Secondary  
39 outcomes were Alzheimer's disease (AD), vascular dementia (VD) and mild cognitive  
40 impairment (MCI). Cox proportional hazard models with inverse probability of treatment  
41 weighting (IPTW) were used to estimate the hazard ratios (HR). Sub analyses included  
42 stratification by age, race, renal function, and glycemic control.

43 **Results:** We identified 96,140 and 16,451 new users of metformin and sulfonylureas,  
44 respectively. Mean age was  $66.4 \pm 8.2$  years (48% male, 83% Caucasian). Over the 5-year  
45 follow-up, 3,207 patients developed all cause dementia (2,256 [2.3%] metformin, 951 [5.8%]  
46 sulfonylurea users) and 760 patients developed PD (625 [0.7%] metformin, 135 [0.8%]  
47 sulfonylurea users). After IPTW, HRs for all cause dementia and PD were 0.80 (95%CI  
48 0.73–0.88) and 1.00 (95%CI 0.79–1.27). HRs for AD, VD and MCI were 0.81 (0.70–0.94),  
49 0.79 (0.63–0.99) and 0.91 (0.79–1.04). Stronger associations were observed in patients who  
50 were younger ( $< 75$  years old), Caucasian, and with moderate renal function.

51 **Conclusions:** Metformin users compared with sulfonylureas users were associated with a  
52 lower risk of all cause dementia, AD and VD but not with PD or MCI. Age and renal function  
53 modified risk reduction. Our findings support the hypothesis that metformin provides more  
54 neuroprotection for dementia than sulfonylureas but not for PD, but further work is required  
55 to assess causality.

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

### 56 **What is already known on this topic**

- 57
- People with type 2 diabetes have increased risk of dementia and Parkinson's disease
- 58 and anti-diabetic drugs such as metformin have been proposed as potential novel
- 59 treatments for these neurological conditions
- Observational studies have shown inconsistent results regarding the effect of
- 60 metformin on the risk of dementia and PD
- 61

### 62 **What this study adds**

- 63
- To our knowledge, this study is the largest of its kind and uses a variety of statistical
- 64 methods to reduce bias and validate the robustness of the results to examine the
- 65 association of metformin versus sulfonylureas for multiple neurogenerative
- 66 outcomes.
  - This study supports and extends the current literature regarding the potential

67 neuroprotective benefits of metformin.

  - Further research is required to understand the underlying neuroprotective

68 mechanisms of metformin which may lead to novel drug development opportunities.

69

70

### 71 **How this study might affect research, practice or policy**

- 72
- This study highlights the need for randomized clinical trials and genetic studies to
- 73 confirm our findings to assess causality and understand mechanistic insights which
- 74 could lead to novel disease modifying treatments for dementia
- This study highlights the need for careful consideration of age, race, and renal
- 75 function in selection of participants for clinical trials to address benefits and safety
- 76 concerns for the repurposing of metformin.
- 77

78

79

## 80 INTRODUCTION

81 Neurodegenerative diseases, such as dementia and Parkinson's disease (PD), are  
82 progressive degenerative diseases affecting neurons, which result in irreversible decline in  
83 brain functioning. It is estimated there are 50 million people living with dementia worldwide  
84 and over 6 million people living with PD, with these numbers predicted to increase  
85 substantially over the next decades due to ageing populations[1–3].

86 Type 2 diabetes (diabetes from now on) is a well-established risk factor for dementia[4] and  
87 PD[5] indicating a potential shared pathophysiology involving insulin resistance and  
88 impaired glucose metabolism[6–8]. Given the potential shared pathophysiology it is not  
89 surprising that drugs used to treat diabetes such as metformin are of increased interest for  
90 repurposing as possible novel treatments to treat and slow the progression of PD[9,10],  
91 cognitive decline and dementia[11]. Metformin is a first line anti diabetic medication that  
92 decreases insulin resistance and increases insulin sensitivity[12]. Other anti-diabetic drugs  
93 such as sulfonylureas, which are second line anti diabetic drugs, stimulate the release of  
94 insulin from pancreatic beta cells[13]. Despite approvals of newer drugs, sulfonylureas  
95 remain commonly prescribed after metformin[14]. Previous studies and reviews on the  
96 potential neuroprotective properties of metformin have inconsistently reported that metformin  
97 is associated with reduced risk of dementia or PD[15–17], increased risk[18,19], and no  
98 association[20–22]. Differences in study design, data quality, gender, race representation,  
99 confounding may explain some of these inconsistencies.

100 Given these inconsistencies, the aim of the present study is to examine the associations of  
101 the first line anti diabetic drug metformin compared to the second line drug class  
102 sulfonylureas with: (i) incident all cause dementia and PD, and (ii) with secondary outcomes  
103 of Alzheimer's disease (AD), vascular dementia (VD) and mild cognitive impairment (MCI). In  
104 this study, we use a large cohort of patient records from individual-level electronic health

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

105 records from a large health care provider in the USA (OPTUM® EHR) together with robust  
106 methods that address bias and confounding. We carried out sub analysis stratifying our  
107 population by age, race, renal function, and glycemic control to understand the impact on  
108 these populations. Our approach focussing on both dementia and PD and an analysis  
109 approach to reduce bias offers a novel aspect and substantial contribution to existing  
110 evidence on the impact of metformin and risk of neurodegenerative diseases.

### 111 **RESEARCH DESIGN AND METHODS**

#### 112 **Study Design and Setting**

113 A new user active comparator study was carried out to determine the comparative effect of  
114 metformin versus sulfonylureas users on dementia risk over a 5-year follow up based on an  
115 intention-to-treat approach. We used OPTUM® deidentified Electronic Health Records  
116 (OPTUM® EHR) dataset containing data from primary care and secondary care facilities  
117 from over 100 million patients across the US general population[23]. We had access to  
118 patient data from 01/01/2006 to 01/12/2018 for patients aged 40 years or older. Patient data  
119 was mapped to the Observational Medical Outcomes Partnership Common Data Model  
120 (CDM) v5.3.1[24].

#### 121 **Participants**

122 We included patients who were 50 years or older with a diagnosis of diabetes and at least 1  
123 year of observational data between 2006 and 2018. Included patients were required to have  
124 at least 1 year of follow-up in the database prior to first prescription of metformin or  
125 sulfonylureas (baseline) and be free of any diagnosis of dementia, MCI, or PD prior to their  
126 first prescription. Patients with polycystic ovary syndrome were excluded due to off label use  
127 of metformin. Since renal function can drive choice of anti-diabetic prescription, included  
128 patients were required to have an estimated glomerular filtration rate (eGFR) measure (or  
129 related clinical diagnosis) and a hemoglobin A1c (HbA1c) measurement 1 year before  
130 metformin or sulfonylurea initiation. Those with chronic kidney disease (CKD) levels 4 and 5

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

131 as well as HbA1c levels > 9% were excluded as this is not indicative of metformin new  
132 users. Only patients who remained on monotherapy of either metformin or sulfonylureas for  
133 2 years following first prescription were included in this study. Follow-up began after this 2-  
134 year period and lasted until the end of the 5 years, death, or dementia/PD diagnosis,  
135 whichever occurred first. During follow-up, participants could take additional diabetes  
136 medications, but those who switched between metformin and sulfonylureas were excluded.

### 137 **Variables and data sources**

138 Comorbidities were defined by standard concepts codes based on SNOMED nomenclature  
139 using ATHENA (<https://athena.ohdsi.org/search-terms/terms>) and PHEOBE  
140 (<https://data.ohdsi.org/PHOEBE/>) tools. Clinical codes used define outcome, exposure and  
141 all other variables can be found in the **Supporting Information (Table S1 and 2)**.

142 Primary outcomes were all cause dementia or PD defined using a combination of diagnosis  
143 and prescription records. Secondary outcomes included diagnosis of AD, VD and MCI.  
144 Metformin or sulfonylurea use was extracted from patient prescriptions defined by standard  
145 concepts codes based on RxNorm nomenclatures. Sulfonylureas consisted of  
146 acetohexamide, carbutamide, chlorpropamide, tolazamide, tolbutamide, glibenclamide  
147 (glyburide), glibornuride, gliclazide, glipizide, gliquidone, glisoxepide, glycopyramide or  
148 glimepiride. At least two prescriptions per year between baseline and the beginning of follow-  
149 up were required.

150 The 33 covariates used in this study were age (dichotomized at 75 years), gender, BMI, race  
151 (Caucasian, African American, Asian, other/unknown), smoking status (Current, previous,  
152 never, missing), US state region, comorbidities [angina, arthritis, atrial fibrillation, cancer,  
153 chronic obstructive pulmonary disease (COPD), CKD diagnosis and stages, coronary heart  
154 disease, eye disease, hypertension, heart attack, heart failure, high cholesterol, head injury,  
155 psychiatric disorders, peripheral arterial disease, substance abuse, stroke], health care  
156 utilisation (number of outpatient visits), year of first prescription, lab measurements (HbA1c,

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

157 eGFR) and medications (ACE inhibitors, glucocorticoids, nonsteroidal anti-inflammatory  
158 drugs (NSAIDS), beta-2 agonists, diuretics and angiotensin receptor blockers. For  
159 measurement variables (i.e., HbA1c, eGFR, BMI etc), the value closest to baseline date  
160 within 1 year before metformin or sulfonylurea prescription was taken unless otherwise  
161 stated. BMI was calculated from height and weight when not reported directly. Height  
162 measurements within 5 years before baseline were allowed. BMI measurements lower than  
163 15 kg/m<sup>2</sup> and greater than 60 kg/m<sup>2</sup> were removed, which is consistent with previous  
164 studies[25]. For smoking, unknown or contradictory measurements on the same day were  
165 removed. HbA1c values  $\leq$  2% were removed. CKD stage was extracted from diagnostics  
166 codes or from eGFR values. Other medications (ACE inhibitors, NSAIDS etc) were defined  
167 as at least two prescriptions one year prior to drug initiation.

### 168 **Statistical methods**

169 Baseline demographics were assessed using standardized mean differences (SMD). We  
170 carried out a new user comparator study[26] to estimate the effect of metformin versus  
171 sulfonylureas. A new user design excludes prevalent cases to reduce immortal time and  
172 survivor biases. To account for confounding by indication, we utilised propensity scores (PS)  
173 and implemented inverse probability of treatment weighting (IPTW)[27] to balance the  
174 baseline characteristics. To create the PS model, we included 33 variables specified  
175 previously. For BMI, smoking status, race and location, the missing indicator method was  
176 utilised to account for missingness[28]. IPTW were created and trimmed at 20. We assessed  
177 balance between our groups using SMD with a difference of less than 0.1 (i.e.,10%)  
178 indicating an acceptable balance between covariates, with metformin and sulfonylurea users  
179 after IPTW[29]. Cox proportional hazards models were used with IPTW to estimate the risk  
180 of subsequent primary (all cause dementia, PD) and secondary outcomes (AD, VD, MCI).  
181 The proportional hazards assumption was evaluated using Kaplan–Meier survival curves.  
182 Where proportional hazards assumption were violated analyses were repeated using piece  
183 wise Cox regression. Five negative control outcomes (impacted cerumen, tinnitus, cramp of

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

184 limb, snoring and impingement syndrome of shoulder region)[30] were used to identify  
185 residual confounding unaccounted for by IPTW.

186 We firstly carried out the analysis using the whole cohort secondly split by age (cut off 75  
187 years) for primary outcomes (all cause dementia, PD) and secondary outcomes (AD, VD,  
188 MCI) with and without adjustment for IPTW. In sub analyses, we compared the risk of  
189 outcome in patients with differing renal function, HbA1c levels and race. We dichotomized  
190 eGFR based on CKD staging into three groups (normal [eGFR > 90 mL/min]), moderate  
191 (eGFR = 60-89 mL/min) and poor renal function (eGFR =< 60 mL/min)) and HbA1c at  
192 baseline, was dichotomized at 7%, reflecting diabetes treatment guidelines. We additionally  
193 carried out a variety of sensitivity analyses to test the robustness of our results. Since  
194 diagnosis codes for MCI might capture impairment but this impairment may not be severe  
195 enough to qualify as dementia, we carried out a sensitivity analysis by combining diagnostic  
196 codes from MCI and dementia. Although patients had been on monotherapy use for 2 years  
197 before follow-up there remained the potential for the impact of dementia or PD to influence  
198 medication use. Further sensitivity analysis involved excluding those with a dementia or PD  
199 diagnosis less than 1 year after follow-up to account for potential protopathic bias (i.e.,  
200 reverse causation). Finally, for the main analysis we followed an intent-to-treat framework  
201 therefore we carried out an on-treatment analysis in which discontinued metformin or  
202 sulfonylureas use was censored.

## 203 **RESULTS**

### 204 **Participants**

205 Between 2006 and 2018, we identified 96,140 new users of metformin and 16,451 new  
206 users of sulfonylureas (n = 112,591). A flow diagram showing how these numbers were  
207 obtained after inclusion and exclusion criteria is shown in **Figure 1**.

208

209



Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

210

211

<<FIGURE 1>>

212 **Characteristics of baseline population**

213 From the study population, the mean age ( $\pm$  SD) was  $66.4 \pm 8.2$  years (metformin users  
214 mean age  $65.7 \pm 7.83$ ) and sulfonylureas mean age  $71.0 \pm 8.71$ ), 48% male, 83%  
215 Caucasian with a mean HbA1c of  $6.79\% \pm 0.76$ . In the sample population, 3,207 patients  
216 developed any dementia (2,256 among metformin and 951 sulfonylurea users) and 760  
217 patients developed PD (625 among metformin and 135 sulfonylurea users). All cause  
218 dementia rates were 7.77 and 17.73 per 1000 person-years in metformin and sulfonylureas  
219 users, respectively. PD rates were 2.13 and 2.45 per 1000 person-years in metformin and  
220 sulfonylureas users, respectively. Metformin users were younger, have better renal function,  
221 fewer comorbidities, and take different associated medications (NSAID's, diuretics and  
222 glucocorticoids) compared to sulfonylurea users (**Table 1**). For BMI, 26% of observations  
223 were missing (24% for metformin users and 33% for sulfonylureas users) and for eGFR  
224 0.1% of observations were missing (0.08% for metformin users and 0.38% for sulfonylureas  
225 users).

226 **Table 1. Baseline characteristics of 112,591 patients over 50 years old with type 2**  
227 **diabetes who were new users of either metformin or sulfonylureas between 2006-2018**  
228 **before balancing of characteristics using inverse probability of treatment weighting**  
229 **(IPTW)**

Description	Metformin	Sulfonylureas	SMD (%)
n	96140	16451	
Gender (% male)	46107 (48.0)	8439 (51.3)	6.7
Race (%)			4.3
African American	9659 (10.0)	1535 (9.3)	
Asian	2394 (2.5)	328 (2.0)	
Caucasian	79693 (82.9)	13853 (84.2)	
Other/Unknown	4394 (4.6)	735 (4.5)	
Age at Baseline (mean [SD])	65.65 (7.83)	70.98 (8.71)	64.4
Age Category: < 75 years	81258 (84.5)	9690 (58.9)	59.3
US Region			10.5

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

Midwest (%)	51871 (54.0)	9232 (56.1)	
Northeast (%)	11430 (11.9)	2294 (13.9)	
South (%)	24678 (25.7)	3706 (22.5)	
West (%)	6153 (6.4)	850 (5.2)	
Unknown (%)	2008 (2.1)	369 (2.2)	
eGFR (mean [SD])	88.47 (16.43)	75.48 (21.73)	67.4
CKD Group (%)			67.2
Stage 1	46980 (48.9)	4464 (27.1)	
Stage 2	44276 (46.1)	7708 (46.9)	
Stage 3	4884 (5.1)	4279 (26.0)	
Smoking Status (%)			18.1
Missing	39916 (41.5)	8078 (49.1)	
Current	7992 (8.3)	1083 (6.6)	
Never	24377 (25.4)	3197 (19.4)	
Previous	23855 (24.8)	4093 (24.9)	
HbA1c (mean [SD])	6.76 (0.75)	6.95 (0.83)	24.3
BMI (mean [SD])	33.46 (6.63)	32.24 (6.60)	18.6
BMI Group			25.8
Missing	23243 (24.2)	5481 (33.3)	
Underweight (<20kg/mg <sup>2</sup> )	276 (0.3)	86 (0.5)	
Normal (20-25kg/mg <sup>2</sup> )	4701 (4.9)	1084 (6.6)	
Overweight (25-30kg/mg <sup>2</sup> )	18766 (19.5)	3302 (20.1)	
Obese (>30kg/mg <sup>2</sup> )	49154 (51.1)	6498 (39.5)	
HbA1c Group			27.3
HbA1c: < 7% (< 53 mmol/mol)	62460 (65.0)	8583 (52.2)	
HbA1c: 7-8% (53 -64 mmol/mol)	26245 (27.3)	5721 (34.8)	
HbA1c: > 8 (> 64 mmol/mol)	7435 (7.7)	2147 (13.1)	
Length of Follow-up in Years (mean (SD))	3.02 (1.59)	3.26 (1.60)	15
Year at Frist Prescription (%)			34.7
2007-2008	9016 (9.4)	3190 (19.4)	
2009-2010	13001 (13.5)	2696 (16.4)	
2011-2012	21752 (22.6)	3748 (22.8)	
2013-2014	30202 (31.4)	4325 (26.3)	
2015-2016	22169 (23.1)	2492 (15.1)	
Number of Outpatient Visits prior to baseline (mean [SD])	24.36 (30.39)	25.74 (34.85)	4.2
All cause dementia (%)	2256 (2.3)	951 (5.8)	17.5
AD (%)	754 (0.8)	337 (2.1)	11.1
VD (%)	349 (0.4)	154 (1.0)	7.5
MCI (%)	1414 (1.5)	401 (2.6)	7.5
PD (%)	625 (0.7)	135 (0.8)	2
Hypertension (%)	68050 (70.8)	11601 (70.5)	0.6
COPD (%)	5483 (5.7)	1194 (7.3)	6.3
Chronic Kidney Disease (%)	4655 (4.8)	2740 (16.7)	38.9

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

Stroke/TIA (%)	2147 (2.2)	562 (3.4)	7.1
Heart Attack (%)	954 (1.0)	224 (1.4)	3.4
Angina (%)	11081 (11.5)	1898 (11.5)	0
Heart Failure (%)	2494 (2.6)	1126 (6.8)	20.1
Atrial Fibrillation (%)	9636 (10.0)	2256 (13.7)	11.4
Coronary Artery Disease (%)	1844 (1.9)	535 (3.3)	8.4
Substance Abuse (%)	1131 (1.2)	176 (1.1)	1
Hyperlipidemia (%)	69957 (72.8)	11026 (67.0)	12.5
Head Injury (%)	537 (0.6)	114 (0.7)	1.7
Arthritis (%)	18726 (19.5)	3057 (18.6)	2.3
Major Psychiatric Disorders (%)	11372 (11.8)	1423 (8.6)	10.5
Peripheral Arterial Disease (%)	3287 (3.4)	998 (6.1)	12.5
Eye Disease (%)	3598 (3.7)	711 (4.3)	2.9
Cancer (%)	4275 (4.4)	981 (6.0)	6.8
Ace Inhibitors (%)	38748 (40.3)	7426 (45.1)	9.8
Diuretics (%)	25846 (26.9)	3930 (23.9)	6.9
Beta 2 Agonists (%)	35593 (37.0)	5530 (33.6)	7.1
Angiotensin II Receptor Blockers (%)	21623 (22.5)	3482 (21.2)	3.2
Glucocorticoids (%)	49438 (51.4)	8533 (51.9)	0.9
NSAIDs (%)	32424 (33.7)	4332 (26.3)	16.2

230 Abbreviations: AD: Alzheimer's Disease, VD: vascular Dementia, CKD: Chronic Kidney Disease; eGFR:  
 231 Estimated glomerular filtration rate by measured laboratory value using Mayo Clinic Quadratic. HbA1c:  
 232 haemoglobin A1c; COPD: Chronic obstructive pulmonary disease; MCI: mild cognitive impairment; TIA: Transient  
 233 ischaemic attack, NSAIDs: Non-steroidal anti-inflammatory drugs, SMD (%): standardized mean difference –  
 234 values >10% indicate significant imbalance between groups. CKD group defined using eGFR and/or diagnosis  
 235 code.

236 After IPTW, all variables were balanced between the two groups for the main analysis (SMD  
 237 <0.1) (**Figure 2**). For sub analyses (age, race, renal function, and HbA1c) all variables were  
 238 balanced apart from the race sub analysis where the variable “HbA1c <7%” was unbalanced  
 239 for the race group “unknown/other” (**Supporting information Figures S1-11**).

240

241

<< **FIGURE 2** >>

242

243 **Association of new users of metformin versus sulfonylureas with all cause dementia**

244 **and PD risk**

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

245 For primary outcomes, using Cox regression with IPTW, there was a lower risk of all cause  
246 dementia (HR 0.80; 95%CI 0.73-0.88) when comparing metformin users with sulfonylurea  
247 users, but no difference when comparing risk of PD (HR 1.00; 95%CI 0.79-1.27) (**Figure 3**).  
248 For secondary outcomes, there was a lower risk of AD (HR 0.81; 95%CI 0.70-0.94) but not  
249 for VD or MCI. However, the direction of the effects on VD and MCI, the effects are  
250 consistent with lower risk for metformin users. We found that the associations were stronger  
251 in the younger (age <75) for all cause dementia and secondary outcomes and attenuated in  
252 older ages ( $\geq 75$  years) (**Figure 3**). There were fewer patients who started antidiabetic  
253 treatment after age 75 compared to before 75 (19% vs. 81%, respectively) although average  
254 follow-up length were similar (3.04 vs. 3.06 years). For PD, the older stratum showed an  
255 increased risk of PD for metformin users versus sulfonylurea users. All unadjusted hazard  
256 ratios for all models can be found in the supporting information (**Tables S4-6**).

257

258

<< **FIGURE 3** >>

259

260 Using Kaplan-Meier survival curves, the proportional hazards assumption held for all cause  
261 dementia, AD, MCI, and PD in **Figure 3** apart from VD where there was deviation of  
262 proportional hazards at around 2.5 years (**Supporting information Figure S12**). Therefore,  
263 we repeated the analysis for the whole population using a piece wise Cox regression split at  
264 2.5 years. The results showed only showed a lower HR for metformin users after 2.5 years  
265 (HR 0.64; 95%CI 0.45-0.89) (**Supporting information Table S7**). For sensitivity analyses,  
266 changing to an on-treatment analysis further decreased HRs in favor of metformin for all  
267 cause dementia (HR 0.76; 95%CI 0.68-0.84) (**Supporting Information Table S8**). Removal  
268 of patients who were diagnosed within 1 year of follow-up attenuated results for AD but did  
269 not change the results for other outcomes (**Supporting Information Table S9**). Combining  
270 the earliest dates from MCI and all cause dementia diagnosis had little impact on results (HR  
271 0.82; 95%CI 0.75-0.89). Adjusted hazard ratios for the negative control outcomes were 1.04  
272 (0.96–1.13) for impacted cerumen, 1.10 (0.95–1.30) for tinnitus, 1.01 (0.87–1.18) for cramp

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

273 in limb, 1.06 (0.91–1.24) for snoring, and 1.16 (0.96–1.41) for shoulder impingement  
274 **(Supporting Information Figure S13)**.

275 **The influence of race, renal function, and glycemic control between new users of**  
276 **metformin versus sulfonylureas with dementia and PD risk**

277 In subgroup analyses we explored if our outcomes were influenced by renal function,  
278 glycemic control, or race **(Figure 4)**.

279

280

**<< FIGURE 4 >>**

281

282 In the race subgroup analysis, after IPTW adjustment, metformin users who were Caucasian  
283 (n = 94,395) had a lower risk of all cause dementia (HR 0.79; 95%CI 0.71–0.87), AD (HR  
284 0.77; 95%CI 0.65–0.90) or in sensitivity analysis > 2.5 years for VD (HR 0.64; 95%CI 0.44-  
285 0.94 **Supporting Information Table S7**). There were no differences for other outcomes  
286 compared to sulfonylurea users **(Figure 4)**. There were no differences in risk for other races  
287 however sample numbers were lower (African American 11,224, Asian 2,735, and  
288 other/unknown 5,156). In the renal function subgroup analysis, metformin users with  
289 moderate renal function were associated with lower all cause dementia and AD but no  
290 differences in risk for PD for any renal function group **(Figure 4)**. For VD, metformin users  
291 had a lower HR after 2.5 years (HR 0.59; 95%CI 0.35–0.99) **(Supporting Information**  
292 **Table S7)**. In the glycemic control subgroup analysis, stratifying on baseline HbA1c,  
293 metformin users with either low or high HbA1c levels were associated with a lower risk of all  
294 cause dementia or AD but only HbA1c  $\geq$  7% levels for VD (HR 0.67; 95%CI 0.48-0.94) which  
295 in sensitivity analysis showed risk was lower after 2.5 years (HR 0.57; 95%CI 0.35-0.93).  
296 Unadjusted HRs for for all subgroup analyses in **Figure 4** can be found in the supporting  
297 information **(Table S6)**.

298 **DISCUSSION**

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

299 In this new user active comparator study of 112,591 patients with diabetes, we found new  
300 metformin users were associated with ~20% lower risk of all dementia, AD and VD  
301 compared sulfonylureas users but there was no difference in PD risk or MCI. A lower risk of  
302 dementia in metformin users was also seen in subsets of patients who were younger (<75  
303 years), Caucasian, and those with moderate renal function but there were no differences in  
304 risk in subsets with different glycemic control. Our findings support the hypothesis that  
305 metformin may provide more neuroprotection for dementia than sulfonylureas but not for PD  
306 or MCI.

307 Our results agree with similar active comparator studies, which show a reduction in risk for  
308 all cause dementia in new users of metformin, despite these studies using either smaller,  
309 older, or mainly male populations [15,16,31]. A study using patients older than 65 years from  
310 the USA Veterans Affairs (VA) database [15] showed a lower risk of all cause dementia in  
311 those younger than 75 years old for metformin users (HR 0.89 95%CI 0.79-0.99 n 28,640)  
312 but not for AD or VD. However, a lack of precision in recording specific diagnosis of  
313 dementia, with difficulties in discriminating between AD and other causes, leading to  
314 underreporting of specific dementia diagnosis[32]. This could explain why previous studies  
315 and our present study have not shown reduction of risk in dementia disease subtypes when  
316 stratifying on age[33]. Our results and three other studies [15,31,34] differ from other studies  
317 [19,35,36] which report no association or increased risk of dementia in metformin users  
318 because these studies did not consider confounding by indication. Therefore, results  
319 obtained from these studies may reflect the differences between the characteristics of the  
320 anti-diabetic drug users rather than true treatment effects. Despite these inconsistencies a  
321 Mendelian randomization study has shown metformin reduces AD risk with the *NDUFA2*  
322 gene and mitochondrial function proposed as potential mechanisms in dementia  
323 protection[37]. For patients with VD our results showed there was only a lower risk after 2.5  
324 years of metformin treatment concurrent with a previous study[21] which showed lower risk

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

325 of dementia and AD after longer term use greater than 2 years in patients from the veteran's  
326 affairs database (n 5528).

327 We did not find any association between metformin and MCI compared with sulfonylureas.  
328 MCI populations could contain a mixture of patients who do or do not convert to dementia.  
329 This heterogeneity may have reduced our power to detect any differences. However, a  
330 randomized controlled trial in patients with amnesic MCI indicated metformin users had  
331 better total recall after 12 months but not for other cognitive tests (MMSE, ADAS-cog)[38].  
332 Interestingly, this trial showed that those who were younger, on the highest dose, without  
333 APOE-ε4 and with lower HbA1c had the most benefit.

334 For PD, there are no active comparator studies which compare new users of metformin  
335 versus sulfonylureas only direct comparator studies which compare drug use versus no drug  
336 use. One study using USA veteran data, showed those who took metformin >2 years had  
337 lower risk of PD (HR 0.30 95%CI 0.18-0.85)[21] compared to non users. However, nearly  
338 30% of non-metformin users were taking other anti-diabetic medications. These results  
339 contradict a study using data from Taiwan which showed metformin users are at increased  
340 risk of PD (HR 2.27 95%CI 1.68-307)[19]. Direct effect studies comparing drug use versus  
341 no drug use are prone to confounding by indication and immortal time bias making  
342 observational studies difficult to interpret and generalize. Despite inconsistent results of  
343 observational studies there is evidence from *in vitro*, non-clinical and genetic studies which  
344 highlight the potential neuroprotective benefits of metformin[10,39,40]. In a Mendelian  
345 randomization study, greater genetically predicted expression level of *NDUFAF2* in brain, the  
346 putative target of metformin, was shown to decrease the risk of PD[11]. This means that  
347 although there was no difference in risk between metformin users and sulfonylureas users  
348 observed our study, it remains possible that metformin could reduce risk of PD compared to  
349 those not taking metformin or other anti-diabetics.

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

350 Our age specific findings are consistent with previous studies which indicate metformin may  
351 have more benefit for reducing dementia risk for those who initiate the treatment at a  
352 younger age[15,31]. We also showed that there were, albeit smaller, benefits in those who  
353 were older than 75 years. Differences in study inclusion criteria, demographics and size of  
354 patient populations could explain this difference. Moreover, older patients have more  
355 comorbidities which contribute to dementia risk and hence attenuate any positive drug  
356 effects of metformin. We additionally showed that PD risk was higher in metformin users in  
357 those older than 75 years old which is consistent with a recent meta-analysis and systematic  
358 review (OR 1.66, 95%CI 1.14 to 2.42)[18], however our confidence intervals were large and  
359 close to the null (HR 1.40 95%CI 1.01-1.95) so caution must be taken with this result. In this  
360 study we found baseline HbA1c levels did not modify the effect of metformin on dementia or  
361 PD risk which also consistent with previous studies[15,34]. This could indicate that  
362 metformin's neuroprotective effect is unlikely to be due to better diabetic control but via other  
363 mechanisms[34,41].

364 We did not see protective effects of metformin in different race groups apart from Caucasian  
365 patients which were the most represented group in our study (83%). These results are  
366 consistent with other studies[15,31], but are contradicted by one[16] who showed that  
367 African American patients taking metformin were associated with a reduction in dementia  
368 risk and no reduction in risk in Caucasian patients. Differences in these results and ours  
369 might be explained by our eligibility criteria, which included 2 years of continuous metformin  
370 or sulfonylurea use. Our exclusion criteria may have removed patients from  
371 underrepresented populations who may have a higher burden of diabetes-related  
372 complications and may escalate quicker from monotherapy metformin or sulfonylurea use  
373 limiting the generalizability of our results[42].

374 For renal function, contradictory to a previous study[15] we found that metformin users with  
375 normal renal function did not have any difference in dementia or PD risk compared to  
376 sulfonylurea users. However, this study[15] only categorized renal function into two



Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

377 categories (split by eGFR  $\geq 60$  mL/min) whereas we split renal function into three groups  
378 (normal eGFR  $> 90$  mL/min, moderate eGFR = 60-89 mL/min and poor eGFR  $\leq 60$  mL/min).  
379 Our results indicated that metformin users with poor renal function (eGFR  $\leq 60$  mL/min) may  
380 have reduced dementia and AD risk. However, this group was much smaller potentially due  
381 to the contradictions of metformin in those with renal disease.

382 There are many strengths of this study. Firstly, the large sample size allowed us to  
383 investigate the impact not only of all cause dementia but also specific causes of dementia,  
384 such as Alzheimer's disease and vascular dementia. We used data from both genders unlike  
385 other studies which had  $>90\%$  male populations[15,21]. We carried out a new user active  
386 comparative cohort study design, with IPTW, nested within a population of patients with  
387 diabetes to reduce confounding by indication and other biases. We additionally tested five  
388 negative control outcomes which provided reassurance that no significant residual  
389 confounding remained after adjusting the mentioned covariates using IPTW methods.

390 Limitations of our study are as follows. Firstly, although we addressed many sources of  
391 confounding, it is possible that some sources of confounding were unavailable or  
392 inadequately measured such as physical activity, education, and diet[4,43]. Furthermore, we  
393 used data from OPTUM® EHR from USA which could reduce the generalisability of our  
394 results due to potential differences in prescription patterns, comorbidities, incidence of  
395 diabetes and dementia in other countries.

396 Secondly, dementia and PD tend to be under-diagnosed and under-recorded[32,44], which  
397 may lead to measurement errors in our outcomes and would tend to lead associations  
398 towards the null. We used both diagnosis and prescription records to define our outcomes  
399 which could lead to misclassification due to the off-label use of certain medications[45,46].  
400 Thirdly, we carried out an intention-to-treat analysis and did not include potential add-on  
401 drugs treatments that occurred later or consider antidiabetic treatment switches. This may be  
402 a possible source of confounding and could result in a lack in generalizability. Fourthly, for

## Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

403 dementia and PD, there is a long prodromal and/or preclinical periods[47,48] which may  
404 impact treatment choice and, although in our sensitivity analysis we removed those with a  
405 diagnosis less than 1 year from the start of follow up, this might not be long enough to  
406 completely remove reverse causation biases. Finally, it has been shown that metformin  
407 reduces mortality in patients with diabetes[49], therefore the competing risk of death could  
408 affect our results and interpretation. A recent study[34], jointly modelled risk of dementia and  
409 death with metformin versus sulfonylureas and showed that the competing risk of death is  
410 highly dependent on the baseline mortality rate of the population.

### 411 **CONCLUSIONS**

412 To our knowledge, this study is the largest of its kind and uses a variety of statistical  
413 methods to reduce bias and validate the robustness of the results. This study supports and  
414 extends the current literature regarding the potential neuroprotective benefits of metformin.  
415 The clinical applicability of this study showing potential neuroprotection of metformin is  
416 highlighted by recent clinical trials underway investigating metformin for the prevention of  
417 cognitive impairment and dementia[11,50]. Furthermore, recent genetic studies also  
418 highlight causal effects between metformin and dementia. This work highlights the need for  
419 careful consideration of age, race, and renal function in selection of participants for clinical  
420 trials to address benefits and safety concerns for the repurposing of metformin. Further  
421 research is required to understand the underlying neuroprotective mechanisms of metformin  
422 which may lead to novel drug development opportunities.

### 423 **DECLARATIONS**

#### 424 **Data availability statement**

425 Data may be obtained from a third party (OPTUM® EHR) and are not publicly available. The  
426 analysis code available via the corresponding author upon request.

#### 427 **Competing interests**

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

428 Alejo J. Nevado-Holgado has received funding from Janssen Pharmaceuticals,  
429 GlaxoSmithKline and Ono Pharma. QSL is an employee of Janssen Research &  
430 Development, LLC, of Johnson & Johnson, and may hold equity in Johnson & Johnson. All  
431 other authors declare no conflicts of interest

#### 432 **Funding**

433 This work was supported by Janssen Pharmaceuticals. Lenore J. Launer is supported by the  
434 National Institute on Aging Intramural Research Programme, US. Additional funds were  
435 provided by Rosetrees Trust (M937) and John Black Charitable Fund (ID A2926). The  
436 funding sources has no role in the study design; in the collection, analysis, and interpretation  
437 of data; in the writing of the report; and in the decision to submit the paper for publication.

#### 438 **Author contributions**

439 DN designed the study with input from LL, QSL and YM. MF carried out data curation and  
440 DN carried out all analyses. DN wrote the manuscript with input from all authors. All authors  
441 reviewed the final manuscript and consent for publication.

#### 442 **Acknowledgments**

443 We thank John Isaac (Janssen Pharmaceuticals) for initial discussions.

#### 444 **REFERENCES**

- 445 1 Martin Prince A, Wimo A, Guerchet M, *et al.* World Alzheimer Report 2015 The  
446 Global Impact of Dementia An Analysis of Prevalence, Incidence, Cost and Trends.  
447 2015.
- 448 2 Ou Z, Pan J, Tang S, *et al.* Global Trends in the Incidence, Prevalence, and Years  
449 Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990  
450 to 2019. *Frontiers in Public Health* 2021;**9**:1994.  
451 doi:10.3389/FPUBH.2021.776847/BIBTEX
- 452 3 Ray Dorsey E, Elbaz A, Nichols E, *et al.* Global, regional, and national burden of  
453 Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of  
454 Disease Study 2016. *The Lancet Neurology* 2018;**17**:939–53. doi:10.1016/S1474-  
455 4422(18)30295-3/ATTACHMENT/30B76483-5DB3-41F7-993B-  
456 E817505F2129/MMC1.PDF
- 457 4 Livingston G, Huntley J, Sommerlad A, *et al.* Dementia prevention, intervention, and  
458 care: 2020 report of the Lancet Commission. *Lancet* 2020;**396**:413–46.  
459 doi:10.1016/S0140-6736(20)30367-6

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

- 460 5 Hassan A, Kandel RS, Mishra R, *et al.* Diabetes Mellitus and Parkinson's Disease:  
461 Shared Pathophysiological Links and Possible Therapeutic Implications. *Cureus*  
462 2020;**12**. doi:10.7759/CUREUS.9853
- 463 6 Karki R, Kodamullil AT, Hofmann-Apitius M. Comorbidity Analysis between  
464 Alzheimer's Disease and Type 2 Diabetes Mellitus (T2DM) Based on Shared  
465 Pathways and the Role of T2DM Drugs. *J Alzheimers Dis* 2017;**60**:721–31.  
466 doi:10.3233/JAD-170440
- 467 7 Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: A new target for  
468 disease modification? *Progress in Neurobiology* 2016;**145–146**:98–120.  
469 doi:10.1016/J.PNEUROBIO.2016.10.001
- 470 8 Firbank MJ, Yarnall AJ, Lawson RA, *et al.* Cerebral glucose metabolism and cognition  
471 in newly diagnosed Parkinson's disease: ICICLE-PD study. *Journal of Neurology,*  
472 *Neurosurgery & Psychiatry* 2017;**88**:310–6. doi:10.1136/JNNP-2016-313918
- 473 9 Agostini F, Masato A, Bubacco L, *et al.* Metformin Repurposing for Parkinson  
474 Disease Therapy: Opportunities and Challenges. *International Journal of Molecular*  
475 *Sciences* 2022;**23**. doi:10.3390/IJMS23010398
- 476 10 Storm CS, Kia DA, Almramhi MM, *et al.* Finding genetically-supported drug targets  
477 for Parkinson's disease using Mendelian randomization of the druggable genome.  
478 *Nature Communications* 2021 *12:1* 2021;**12**:1–14. doi:10.1038/s41467-021-26280-1
- 479 11 METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability  
480 in Older Adults at Risk for Dementia - Full Text View - ClinicalTrials.gov.  
481 <https://clinicaltrials.gov/ct2/show/NCT05109169> (accessed 23 Mar 2022).
- 482 12 Rojas LBA, Gomes MB. Metformin: An old but still the best treatment for type 2  
483 diabetes. *Diabetology and Metabolic Syndrome*. 2013;**5**. doi:10.1186/1758-5996-5-6
- 484 13 Sola D, Rossi L, Schianca GPC, *et al.* Sulfonylureas and their use in clinical practice.  
485 *Archives of Medical Science* □: *AMS* 2015;**11**:840. doi:10.5114/AOMS.2015.53304
- 486 14 Roglic G, Norris SL. Medicines for Treatment Intensification in Type 2 Diabetes and  
487 Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of  
488 the World Health Organization Guidelines on Second- and Third-Line Medicines and  
489 Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With  
490 Diabetes Mellitus. *Ann Intern Med* 2018;**169**:394–7. doi:10.7326/M18-1149
- 491 15 Orkaby AR, Cho K, Cormack J, *et al.* Metformin vs sulfonylurea use and risk of  
492 dementia in US veterans aged ≥65 years with diabetes. *Neurology* 2017;**89**:1877–85.  
493 doi:10.1212/WNL.0000000000004586
- 494 16 Scherrer JF, Morley JE, Salas J, *et al.* Association between metformin initiation and  
495 incident dementia among African American and white veterans health administration  
496 patients. *Annals of Family Medicine* 2019;**17**:352–62. doi:10.1370/afm.2415
- 497 17 Campbell JM, Stephenson MD, De Courten B, *et al.* Metformin Use Associated with  
498 Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-  
499 Analysis. *Journal of Alzheimer's Disease* 2018;**65**:1225–36. doi:10.3233/JAD-180263
- 500 18 Ping F, Jiang N, Li Y. Association between metformin and neurodegenerative diseases  
501 of observational studies: systematic review and meta-analysis. *BMJ Open Diabetes*  
502 *Research and Care* 2020;**8**:e001370. doi:10.1136/BMJDR-2020-001370
- 503 19 Kuan YC, Huang KW, Lin CL, *et al.* Effects of metformin exposure on  
504 neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. *Prog*  
505 *Neuropsychopharmacol Biol Psychiatry* 2017;**79**:77–83.  
506 doi:10.1016/J.PNPBP.2017.06.002
- 507 20 Sluggett JK, Koponen M, Simon Bell J, *et al.* Metformin and Risk of Alzheimer's  
508 Disease Among Community-Dwelling People With Diabetes: A National Case-Control  
509 Study. *J Clin Endocrinol Metab* 2020;**105**:E963–72. doi:10.1210/CLINEM/DGZ234

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

- 510 21 Shi Q, Liu S, Fonseca VA, *et al.* Effect of metformin on neurodegenerative disease  
511 among elderly adult US veterans with type 2 diabetes mellitus. *BMJ Open* 2019;**9**.  
512 doi:10.1136/bmjopen-2018-024954
- 513 22 Qin X, Zhang X, Li P, *et al.* Association Between Diabetes Medications and the Risk  
514 of Parkinson's Disease: A Systematic Review and Meta-Analysis. *Frontiers in*  
515 *Neurology* 2021;**12**:1155. doi:10.3389/FNEUR.2021.678649/BIBTEX
- 516 23 Wallace PJ, Shah ND, Dennen T, *et al.* Optum Labs: Building A Novel Node In The  
517 Learning Health Care System. *Health Affairs* 2014;**33**:1187–94.  
518 doi:10.1377/hlthaff.2014.0038
- 519 24 Marc Overhage J, Ryan PB, Reich CG, *et al.* Validation of a common data model for  
520 active safety surveillance research. *J Am Med Inform Assoc* 2012;**19**:54–60.  
521 doi:10.1136/AMIAJNL-2011-000376
- 522 25 Newby D, Prieto-Alhambra D, Duarte-Salles T, *et al.* Methotrexate and relative risk of  
523 dementia amongst patients with rheumatoid arthritis: a multi-national multi-database  
524 case-control study. *Alzheimers Res Ther* 2020;**12**. doi:10.1186/S13195-020-00606-5
- 525 26 The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance  
526 (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision  
527 8). EMA/95098/2010  
528 [http://www.encepp.eu/standards\\_and\\_guidances/documents/GuideMethodRev8.pdf](http://www.encepp.eu/standards_and_guidances/documents/GuideMethodRev8.pdf).
- 529 27 Curtis LH, Hammill BG, Eisenstein EL, *et al.* Using inverse probability-weighted  
530 estimators in comparative effectiveness analyses with observational databases. *Med*  
531 *Care* 2007;**45**. doi:10.1097/MLR.0B013E31806518AC
- 532 28 Groenwold RHH, White IR, Donders ART, *et al.* Missing covariate data in clinical  
533 research: When and when not to use the missing-indicator method for analysis. *CMAJ*  
534 2012;**184**:1265–9. doi:10.1503/CAJ.110977/-/DC1
- 535 29 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates  
536 between treatment groups in propensity-score matched samples. *Stat Med*  
537 2009;**28**:3083–107. doi:10.1002/SIM.3697
- 538 30 Arnold BF, Ercumen A, Benjamin-Chung J, *et al.* Brief report: Negative controls to  
539 detect selection bias and measurement bias in epidemiologic studies. *Epidemiology*  
540 2016;**27**:637–41. doi:10.1097/EDE.0000000000000504
- 541 31 Scherrer JF, Salas J, Floyd JS, *et al.* Metformin and Sulfonylurea Use and Risk of  
542 Incident Dementia. *Mayo Clin Proc* 2019;**94**:1444.  
543 doi:10.1016/J.MAYOCP.2019.01.004
- 544 32 Davis KAS, Mueller C, Ashworth M, *et al.* What gets recorded, counts: dementia  
545 recording in primary care compared with a specialist database. *Age Ageing*  
546 2021;**50**:2206–13. doi:10.1093/AGEING/AFAB164
- 547 33 McKhann GM, Knopman DS, Chertkow H, *et al.* The diagnosis of dementia due to  
548 Alzheimer's disease: recommendations from the National Institute on Aging-  
549 Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.  
550 *Alzheimers Dement* 2011;**7**:263–9. doi:10.1016/J.JALZ.2011.03.005
- 551 34 Charpignon M-L, Vakulenko-Lagun B, Zheng B, *et al.* Drug repurposing of metformin  
552 for Alzheimer's disease: Combining causal inference in medical records data and  
553 systems pharmacology for biomarker identification. *medRxiv*  
554 2021;:2021.08.10.21261747. doi:10.1101/2021.08.10.21261747
- 555 35 Weinstein G, Davis-Plourde KL, Conner S, *et al.* Association of metformin,  
556 sulfonylurea and insulin use with brain structure and function and risk of dementia and  
557 Alzheimer's disease: Pooled analysis from 5 cohorts. *PLoS One* 2019;**14**.  
558 doi:10.1371/JOURNAL.PONE.0212293



Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

- 559 36 Ha J, Choi DW, Kim KJ, *et al.* Association of metformin use with Alzheimer's disease  
560 in patients with newly diagnosed type 2 diabetes: a population-based nested case-  
561 control study. *Scientific Reports* 2021 11:1 2021;**11**:1–9. doi:10.1038/s41598-021-  
562 03406-5
- 563 37 Zheng J, Xu M, Walker V, *et al.* Evaluating the efficacy and mechanism of metformin  
564 targets on reducing Alzheimer's disease risk in the general population: a Mendelian  
565 randomization study. *medRxiv* 2022;:2022.04.09.22273625.  
566 doi:10.1101/2022.04.09.22273625
- 567 38 Luchsinger JA, Perez T, Chang H, *et al.* Metformin in Amnesic Mild Cognitive  
568 Impairment: results of a pilot randomized placebo controlled clinical trial. *J*  
569 *Alzheimers Dis* 2016;**51**:501. doi:10.3233/JAD-150493
- 570 39 Sportelli C, Urso D, Jenner P, *et al.* Metformin as a Potential Neuroprotective Agent in  
571 Prodromal Parkinson's Disease—Viewpoint. *Frontiers in Neurology* 2020;**11**:556.  
572 doi:10.3389/FNEUR.2020.00556/BIBTEX
- 573 40 Mor DE, Sohrabi S, Kaletsky R, *et al.* Metformin rescues Parkinson's disease  
574 phenotypes caused by hyperactive mitochondria. *Proc Natl Acad Sci U S A*  
575 2020;**117**:26438–47.  
576 doi:10.1073/PNAS.2009838117/SUPPL\_FILE/PNAS.2009838117.SD02.XLSX
- 577 41 Lee ATC, Richards M, Chan WC, *et al.* Higher dementia incidence in older adults with  
578 type 2 diabetes and large reduction in HbA1c. *Age and Ageing* 2019;**48**:838–44.  
579 doi:10.1093/AGEING/AFZ108
- 580 42 Haw JS, Shah M, Turbow S, *et al.* Diabetes Complications in Racial and Ethnic  
581 Minority Populations in the USA. *Current Diabetes Reports* 2021 21:1 2021;**21**:1–8.  
582 doi:10.1007/S11892-020-01369-X
- 583 43 Lourida I, Soni M, Thompson-Coon J, *et al.* Mediterranean diet, cognitive function,  
584 and dementia: a systematic review. *Epidemiology* 2013;**24**:479–89.  
585 doi:10.1097/EDE.0B013E3182944410
- 586 44 Okunoye O, Marston L, Walters K, *et al.* Change in the incidence of Parkinson's  
587 disease in a large UK primary care database. *npj Parkinson's Disease* 2022 8:1  
588 2022;**8**:1–7. doi:10.1038/s41531-022-00284-0
- 589 45 Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for  
590 psychiatric disorders. *Progress in Neuro-Psychopharmacology and Biological*  
591 *Psychiatry* 2008;**32**:1362–74. doi:10.1016/J.PNPBP.2008.01.008
- 592 46 Schwartz TL, Siddiqui UA, Raza S. Memantine as an Augmentation Therapy for  
593 Anxiety Disorders. *Case Reports in Psychiatry* 2012;**2012**:1–3.  
594 doi:10.1155/2012/749796
- 595 47 Fereshtehnejad SM, Yao C, Pelletier A, *et al.* Evolution of prodromal Parkinson's  
596 disease and dementia with Lewy bodies: a prospective study. *Brain* 2019;**142**:2051–  
597 67. doi:10.1093/BRAIN/AWZ111
- 598 48 Vermunt L, Sikkes SAM, van den Hout A, *et al.* Duration of Preclinical, Prodromal  
599 and Dementia Alzheimer Disease Stages in Relation to Age, Sex, and APOE genotype.  
600 *Alzheimers Dement* 2019;**15**:888. doi:10.1016/J.JALZ.2019.04.001
- 601 49 Maruthur NM, Tseng E, Hutfless S, *et al.* Diabetes Medications as Monotherapy or  
602 Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review  
603 and Meta-analysis. *Ann Intern Med* 2016;**164**:740–51. doi:10.7326/M15-2650
- 604 50 Metformin in Alzheimer's Dementia Prevention - Full Text View - ClinicalTrials.gov.  
605 <https://clinicaltrials.gov/ct2/show/NCT04098666> (accessed 9 May 2022).  
606  
607

608 **FIGURE LEGENDS**

Newby 2022 Metformin versus sulfonylureas on Dementia and Parkinson's risk

609  
610 **Figure 1. Flow diagram sample population for this study after inclusion and exclusion**  
611 **criteria; eGFR: Estimated glomerular filtration rate, HbA1c: Hemoglobin A1c; PCOS:**  
612 **polycystic ovary syndrome; PD: Parkinson's Disease**

613 **Figure 2: Covariate balance between new users of metformin and sulfonylureas using**  
614 **absolute Standardized Mean Differences (SMD) before (unweighted) and after inverse**  
615 **probability of treatment weighting (weighted) for whole cohort (n = 112,591). Dotted**  
616 **line indicates SMD cut off at 0.1 where >0.1 indicates difference in covariates between**  
617 **the metformin and sulfonylurea users. CKD: Chronic Kidney Disease; eGFR:**  
618 **Estimated glomerular filtration rate. HbA1c: haemoglobin A1c; COPD: Chronic**  
619 **obstructive pulmonary disease, NSAIDs: Non-steroidal anti-inflammatory drugs**

620 **Figure 3: Forest plot showing IPTW weighted associations of primary and secondary**  
621 **outcomes with new users of metformin versus sulfonylureas in whole population**  
622 **(over 50) and stratified for patients above and below 75 years of age HR: hazard ratio,**  
623 **CI confidence interval, IPTW inverse probability treatment weight**

624 **Figure 4: Forest plot showing IPTW weighted associations of primary and secondary**  
625 **outcomes with new users of metformin versus sulfonylureas stratified by race,**  
626 **baseline renal function and baseline HbA1c. Renal function levels were defined as**  
627 **normal (eGFR > 90 mL/min), moderate (eGFR = 60-89 mL/min) and poor (eGFR = < 60**  
628 **mL/min). HbA1c levels were defined as low < 7% and high => 7%. HR: hazard ratio, CI**  
629 **confidence interval, IPTW inverse probability treatment weight.**

630

631

Patients 50+ years with Diabetes  
with at least 1 year of continued observation  
(n = 4119603)

Patients with any prescription  
for Metformin with at  
least 2 years exposure (n = 639459)

Patients with any prescription  
for Sulphonylureas with at  
least 2 years exposure (n = 343865)

Excluded Patients  
(n = 407901):  
1) Taking any Sulphonylureas  
2) Taking other anti diabetics or  
insulin in first 2 years of  
Metformin exposure

Excluded Patients  
(n = 294522):  
1) Taking Metformin  
2) Taking other anti diabetics or  
insulin in first 2 years of  
Sulphonylureas exposure

New Drug Users of  
Metformin (n = 231558)

New Drug Users of  
Sulphonylureas (n = 49343)

Excluded Patients  
(n = 135418):  
1) No renal function information  
or eGFR Stages > 3  
2) Dementia/PD prior to drug use  
3) Hb1Ac > 9% (> 75 mmol/mol)  
4) Diagnosis of PCOS

Excluded Patients  
(n = 32892):  
1) No renal function information  
or eGFR Stages > 3  
2) Dementia/PD prior to drug use  
3) Hb1Ac > 9% (> 75 mmol/mol)  
4) Diagnosis of PCOS

Target Group: Metformin  
(n = 96140)

Comparator Group: Sulphonylureas  
(n = 16451)

End of Follow up:  
1) Dementia/PD Diagnosis  
2) Death  
3) End of Study



# Covariate Balance





